Literature DB >> 17878195

No evidence of misdiagnosis in patients with multiple sclerosis and repeated positive anticardiolipin antibody testing based on magnetic resonance imaging and long term follow-up.

M Liedorp1, E Sanchez, I M W van Hoogstraten, B M E von Blomberg, F Barkhof, C H Polman, J Killestein.   

Abstract

OBJECTIVE: To determine whether patients with definite multiple sclerosis (MS) and repeated positive anticardiolipin antibody (aCL Ab) testing fulfil the recently updated criteria for the antiphospholipid syndrome (APS). Also, to determine if these patients form a separate subgroup in terms of long term follow-up and MRI characteristics.
DESIGN: A blinded case control study comparing MRI patterns between aCL Ab positive and negative MS patients with a clinical follow-up of 7 years. PARTICIPANTS: 8 (5.6%; male:female ratio 2:6; 6 relapsing-remitting subtype, 1 primary progressive subtype and 1 neuromyelitis optica (NMO)) of 143 consecutive patients with definite MS or NMO (71% relapsing-remitting, 18% secondary progressive and 6% primary progressive disease course; 4% NMO) showed repeated positive aCL Ab testing.
SETTING: Outpatient clinic of a tertiary MS centre in The Netherlands.
RESULTS: All eight aCL Ab positive patients had levels below 40 MPL/GPL units, with the majority of intervals between tests of at least 12 weeks. After follow-up, none of the patients fulfilled the criteria for APS. No specific MRI features were present compared with 24 matched aCL Ab negative patients.
CONCLUSIONS: No aCL Ab positive MS patient fulfilled the criteria for APS, arguing against a possible misdiagnosis or coexistence.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17878195      PMCID: PMC2117534          DOI: 10.1136/jnnp.2007.117713

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  14 in total

1.  ELISA for the detection of anticardiolipin antibodies. High specificity based on the use of adult bovine serum as buffer and systematic subtraction of non-specific binding.

Authors:  A Rupin; Y Gruel; H Watier; A C Girard; J Leroy; P Bardos
Journal:  J Immunol Methods       Date:  1991-04-25       Impact factor: 2.303

2.  A comparative audit of anticardiolipin antibodies in oligoclonal band negative and positive multiple sclerosis.

Authors:  Janek Vilisaar; Martin Wilson; Graham Niepel; Lance D Blumhardt; Cris S Constantinescu
Journal:  Mult Scler       Date:  2005-08       Impact factor: 6.312

3.  Antiphospholipid antibody ELISAs: survey on the performance of clinical laboratories assessed by using lyophilized affinity-purified IgG with anticardiolipin and anti-beta2-Glycoprotein I activity.

Authors:  Vittorio Pengo; Alessandra Biasiolo; Elisa Bison; Veena Chantarangkul; Armando Tripodi
Journal:  Thromb Res       Date:  2006-10-03       Impact factor: 3.944

4.  Systemic autoimmune features and multiple sclerosis: a 5-year follow-up study.

Authors:  A Tourbah; A Clapin; O Gout; B Fontaine; R Liblau; F Batteux; J L Stiévenart; B Weill; C Lubetzki; O Lyon-Caen
Journal:  Arch Neurol       Date:  1998-04

5.  Thrombosis, abortion, cerebral disease, and the lupus anticoagulant.

Authors:  G R Hughes
Journal:  Br Med J (Clin Res Ed)       Date:  1983-10-15

6.  Anticardiolipin antibodies are not a useful screening tool in a nonselected large group of patients with multiple sclerosis.

Authors:  J Sastre-Garriga; J C Reverter; J Font; M Tintoré; G Espinosa; X Montalban
Journal:  Ann Neurol       Date:  2001-03       Impact factor: 10.422

7.  Anticardiolipin antibodies in patients with multiple sclerosis do not represent a subgroup of patients according to clinical, familial, and biological characteristics.

Authors:  O Heinzlef; B Weill; C Johanet; V Sazdovitch; S Caillat-Zucman; E Tournier-Lasserve; E Roullet
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-05       Impact factor: 10.154

Review 8.  Multiple sclerosis, neuropsychiatric lupus and antiphospholipid syndrome: where do we stand?

Authors:  S Ferreira; D P D'Cruz; G R V Hughes
Journal:  Rheumatology (Oxford)       Date:  2005-01-11       Impact factor: 7.580

9.  Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus.

Authors:  E N Harris; A E Gharavi; M L Boey; B M Patel; C G Mackworth-Young; S Loizou; G R Hughes
Journal:  Lancet       Date:  1983-11-26       Impact factor: 79.321

Review 10.  Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria".

Authors:  Chris H Polman; Stephen C Reingold; Gilles Edan; Massimo Filippi; Hans-Peter Hartung; Ludwig Kappos; Fred D Lublin; Luanne M Metz; Henry F McFarland; Paul W O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Brian G Weinshenker; Jerry S Wolinsky
Journal:  Ann Neurol       Date:  2005-12       Impact factor: 10.422

View more
  2 in total

Review 1.  Non-stroke Central Neurologic Manifestations in Antiphospholipid Syndrome.

Authors:  Cécile M Yelnik; Elizabeth Kozora; Simone Appenzeller
Journal:  Curr Rheumatol Rep       Date:  2016-02       Impact factor: 4.592

2.  Autoantibodies and Sjogren's Syndrome in multiple sclerosis, a reappraisal.

Authors:  Andrew J Solomon; William Hills; Zunqiu Chen; James Rosenbaum; Dennis Bourdette; Ruth Whitham
Journal:  PLoS One       Date:  2013-06-12       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.